Scholarlink

<p>Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic cardiomyopathy (ACM) is a crucial yet challenging procedure, given the evolving disease definitions, diverse subtypes, genetic variability, complexities in risk stratification, and the intricate substrate distribution characteristic of this condition. Initially described as a right ventricular cardiomyopathy (ARVC), ACM now encompasses left-dominant (ALVC) and biventricular (ABVC) phenotypes, driven by desmosomal (e.g., DSP, PKP2) and non-desmosomal (e.g., FLNC, LMNA) mutations, with fibrosis as the primary arrhythmic substrate. Catheter ablation, particularly combined endocardial-epicardial approaches, reduces VT burden but faces high recurrence rates in younger patients and those with extensive scarring. In this review, we critically assess the role of VT ablation in ACM, current evidence, available techniques for mapping and ablation, outcomes and predictors of success of the ablation procedure in this patient group.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in VT ablation for arrhythmogenic cardiomyopathy: evidence, mapping and ablation strategies, and predictive factors

  • 期刊论文

  • 发表日期：

    2025年10月27日

查看全文
  • Mohamed Abdelazeem,
  • Amir Abdelghany,
  • Mohamed Sharief,
  • Ahmed Ammar

摘要

Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic cardiomyopathy (ACM) is a crucial yet challenging procedure, given the evolving disease definitions, diverse subtypes, genetic variability, complexities in risk stratification, and the intricate substrate distribution characteristic of this condition. Initially described as a right ventricular cardiomyopathy (ARVC), ACM now encompasses left-dominant (ALVC) and biventricular (ABVC) phenotypes, driven by desmosomal (e.g., DSP, PKP2) and non-desmosomal (e.g., FLNC, LMNA) mutations, with fibrosis as the primary arrhythmic substrate. Catheter ablation, particularly combined endocardial-epicardial approaches, reduces VT burden but faces high recurrence rates in younger patients and those with extensive scarring. In this review, we critically assess the role of VT ablation in ACM, current evidence, available techniques for mapping and ablation, outcomes and predictors of success of the ablation procedure in this patient group.

Graphical Abstract